AIM ImmunoTech Inc.

0.4311-0.0159-3.56%Vol 79.96K1Y Perf -23.20%
Oct 4th, 2023 15:59 DELAYED
BID0.4292 ASK0.4400
Open0.4260 Previous Close0.4470
Pre-Market- After-Market0.43
 - -  0.00 -0.26%
Target Price
3.00 
Analyst Rating
Strong Buy 1.00
Potential %
595.89 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★+     57.97
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★+     53.19
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
25.71 
Earnings Rating
Market Cap20.98M 
Earnings Date
21st Nov 2023
Alpha-0.01 Standard Deviation0.29
Beta-0.05 

Today's Price Range

0.42020.4500

52W Range

0.29100.8359

5 Year PE Ratio Range

-1.70-1.50

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-2.99%
1 Month
-26.96%
3 Months
-33.58%
6 Months
0.36%
1 Year
-23.20%
3 Years
-79.77%
5 Years
-95.68%
10 Years
-99.97%

TickerPriceChg.Chg.%
AIM0.4311-0.0159-3.56
AAPL173.661.26000.73
GOOG136.272.97002.23
MSFT318.965.56501.78
XOM111.50-4.3300-3.74
WFC38.970.30000.78
JNJ155.520.18000.12
FB196.640.99000.51
GE108.851.09001.01
JPM143.350.64000.45
Financial StrengthValueIndustryS&P 500US Markets
12.70
14.20
0.02
0.02
-1 138.30
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
-30.40
-15 483.00
-15 275.60
-6 361.50
-
RevenueValueIndustryS&P 500US Markets
85.00K
0.00
-16.96
-12.96
Earnings HistoryEstimateReportedSurprise %
Q01 2024--0.10-
Q03 2022--0.13-
Q02 2022--0.10-
Q03 2021--0.08-
Q02 2021--0.12-
Q01 2021--0.08-
Q04 2020--0.09-
Q03 2020--0.08-
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date21st Nov 2023
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume79.96K
Shares Outstanding48.67K
Shares Float47.76M
Trades Count229
Dollar Volume34.24K
Avg. Volume130.43K
Avg. Weekly Volume146.04K
Avg. Monthly Volume124.04K
Avg. Quarterly Volume121.20K

AIM ImmunoTech Inc. (AMEX: AIM) stock closed at 0.447 per share at the end of the most recent trading day (a -1.97% change compared to the prior day closing price) with a volume of 219.25K shares and market capitalization of 20.98M. Is a component of indices and it is traded on AMEX exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 23 people. AIM ImmunoTech Inc. CEO is Thomas K. Equels.

The one-year performance of AIM ImmunoTech Inc. stock is -23.2%, while year-to-date (YTD) performance is 43.32%. AIM stock has a five-year performance of -95.68%. Its 52-week range is between 0.291 and 0.8359, which gives AIM stock a 52-week price range ratio of 25.71%

AIM ImmunoTech Inc. currently has a PE ratio of -1.10, a price-to-book (PB) ratio of 0.55, a price-to-sale (PS) ratio of 228.80, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -39.48%, a ROC of -40.08% and a ROE of -41.84%. The company’s profit margin is -%, its EBITDA margin is -15 275.60%, and its revenue ttm is $85.00 Thousand , which makes it $0.00 revenue per share.

Of the last four earnings reports from AIM ImmunoTech Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. AIM ImmunoTech Inc.’s next earnings report date is 21st Nov 2023.

The consensus rating of Wall Street analysts for AIM ImmunoTech Inc. is Strong Buy (1), with a target price of $3, which is +595.89% compared to the current price. The earnings rating for AIM ImmunoTech Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

AIM ImmunoTech Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

AIM ImmunoTech Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 32.58, ATR14 : 0.05, CCI20 : -138.17, Chaikin Money Flow : -0.13, MACD : -0.05, Money Flow Index : 19.29, ROC : -26.33, RSI : 30.87, STOCH (14,3) : 15.82, STOCH RSI : 0.24, UO : 39.28, Williams %R : -84.18), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of AIM ImmunoTech Inc. in the last 12-months were: Appelrouth Stewart (Buy at a value of $25 000), Equels Thomas (Buy at a value of $50 000), Equels Thomas K (Buy at a value of $10 000), Peter W. Rodino (Buy at a value of $25 000), Rodino Peter (Buy at a value of $25 000), Stewart L. Appelrouth (Buy at a value of $25 000), Thomas K. Equels (Buy at a value of $50 000)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

AIM ImmunoTech Inc.

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

CEO: Thomas K. Equels

Telephone: +1 352 448-7797

Address: 2117 SW Highway 484, Ocala 34473, FL, US

Number of employees: 23

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

52%48%

Bearish Bullish

57%43%

Bearish Bullish

60%40%

 

TipRanks News for AIM


News

Stocktwits